Can Retatrutide Cause Hair Loss?

Retatrutide is an investigational triple receptor agonist developed by Eli Lilly that has no marketing authorisation in the UK or elsewhere. Questions about whether retatrutide can cause hair loss are understandable, given that significant weight loss from any cause is a recognised trigger of a temporary shedding condition called telogen effluvium. This article outlines what is currently known from clinical trial data, explains the biological mechanism behind weight-loss-related hair shedding, and describes when to seek medical advice if hair loss occurs during participation in an authorised trial.

What is retatrutide and what is its regulatory status in the UK?

Retatrutide has no UK marketing authorisation and can only be accessed within an authorised clinical trial. It is an investigational triple receptor agonist targeting GLP-1, GIP and glucagon receptors.

Retatrutide holds no marketing authorisation in the UK or anywhere else, and it can be prescribed or supplied only within an authorised clinical trial.^[1] It is an investigational medicine developed by Eli Lilly that acts as a triple receptor agonist, targeting the glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP) and glucagon receptors simultaneously. This triple mechanism is intended to influence both energy intake and energy expenditure, though its clinical profile is still being characterised through ongoing research.

Because retatrutide has no UK marketing authorisation, it cannot be obtained through a GP, a pharmacy or any online clinic. Anything sold or supplied outside an authorised clinical trial is not a licensed product and may be falsified, posing serious risks to health. The MHRA has not authorised retatrutide, and no timeline for a potential application can be given.

For people interested in weight management treatment now, licensed options exist and can be discussed with a GP. The regulatory and safety evidence base for retatrutide continues to develop through named clinical programmes including TRIUMPH-1 to TRIUMPH-4 and TRANSCEND-T2D-1, and any conclusions about its benefit-risk profile must await the full results of those authorised trials.^[5]

Why do weight-loss treatments sometimes trigger hair shedding?

Rapid weight loss from any cause can shift hair follicles into the resting phase, producing telogen effluvium, with shedding typically noticeable two to four months after the triggering event.

Significant caloric restriction and rapid weight loss are well-recognised triggers of a temporary hair-shedding condition called telogen effluvium, which can occur with any treatment or dietary approach that produces substantial weight reduction. Telogen effluvium happens when a physiological stress, such as a sharp reduction in calorie intake or rapid body weight change, causes a larger than usual proportion of hair follicles to shift simultaneously into the resting (telogen) phase of the hair growth cycle.^[10][11] Shedding typically becomes noticeable two to four months after the triggering event and usually resolves on its own once the body adapts.

This mechanism is not unique to any particular medicine. It has been observed with bariatric surgery, very low calorie diets and GLP-1 receptor agonist treatments. The hair follicle is metabolically active and sensitive to nutritional status, so deficiencies in protein, iron, zinc or biotin, which can accompany rapid weight loss, may compound the effect.

It is important to distinguish telogen effluvium from other causes of hair loss, such as thyroid dysfunction, iron deficiency anaemia or androgenetic alopecia, all of which require separate investigation and management. If hair shedding is a concern, a GP can arrange appropriate blood tests to rule out an underlying cause. Maintaining adequate protein intake and nutritional balance during any weight-loss programme is generally advisable, though specific supplementation should only be taken on medical advice.

What side effects were reported in retatrutide clinical trials?

The most commonly reported adverse effects in the Phase 2 trial were gastrointestinal, including nausea, vomiting and diarrhoea. Hair loss was not identified as a primary safety signal in published data.

Hair loss was not identified as a primary safety signal in the published Phase 2 retatrutide trial data, though the evidence base is still developing through the ongoing TRIUMPH and TRANSCEND programmes. The Phase 2 trial, published in the New England Journal of Medicine in 2023, enrolled adults with obesity over 48 weeks and reported that the most commonly observed adverse effects were gastrointestinal in nature, including nausea, vomiting, diarrhoea and constipation.^[2][3] These were generally described as mild to moderate and more frequent during dose escalation.

Hair thinning or shedding was not among the adverse events highlighted in the Phase 2 publication, but it is worth noting that trial populations and reporting periods may not capture every effect that emerges in broader or longer-term use.^[2][3] The TRIUMPH-1 to TRIUMPH-4 trials and TRANSCEND-T2D-1 are designed to provide a more comprehensive safety and efficacy picture across larger populations and longer durations, and their full results will be important for understanding the complete adverse effect profile.

Given that retatrutide produced substantial weight loss in trial participants, the indirect pathway of telogen effluvium described in the previous section remains biologically plausible, even if it was not specifically reported as a drug-related effect. Suspected side effects experienced by participants within an authorised clinical trial should be reported to the trial team under the study protocol. Suspected adverse reactions can also be reported to the MHRA via the Yellow Card scheme at yellowcard.mhra.gov.uk.

When should you speak to a doctor about hair loss during a trial?

Trial participants should report any hair shedding to their trial team immediately. Sudden, patchy or symptom-accompanied hair loss warrants prompt GP review to exclude underlying conditions.

Any participant in an authorised retatrutide clinical trial who notices hair shedding should report it promptly to their trial team, as this is the correct and required route for safety reporting within a study protocol. The trial team can assess whether the shedding is consistent with telogen effluvium related to weight loss, whether it may indicate a nutritional deficiency, or whether further investigation is warranted. Participants should not attempt to self-manage significant hair loss without guidance from the clinical team overseeing their care.

More broadly, hair loss that is sudden, patchy, associated with scalp changes such as redness or scaling, or accompanied by other symptoms such as fatigue, cold intolerance or swollen glands warrants prompt medical review by a GP. These features may suggest an underlying condition such as thyroid disease, iron deficiency anaemia or alopecia areata, none of which are related to weight-loss treatment and all of which benefit from early diagnosis.

For hair shedding that appears gradual and diffuse, beginning a few months after starting a weight-loss programme, a GP can arrange blood tests to check thyroid function, full blood count, ferritin and relevant nutritional markers. If results are normal and the pattern is consistent with telogen effluvium, reassurance and monitoring are usually appropriate, as the condition is typically self-limiting. Contact your GP to discuss concerns, use NHS 111 for urgent advice outside of surgery hours, and call 999 only in a genuine emergency. There is no need to attend A&E for hair loss alone.

Frequently Asked Questions